Selective inhibition of BET bromodomain and their effect on nuclear factor-kappa B activation in pulmonary arterial hypertension

N. Gambaryan, C. Meng, F. Perros, C. Guignabert, L. Tu, M. Humbert, I. Adcock, S. Wort (London, United Kingdom; Le Plessis-Robinson, France)

Source: Annual Congress 2013 –Pulmonary circulation: basic science
Session: Pulmonary circulation: basic science
Session type: Oral Presentation
Number: 1501
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Gambaryan, C. Meng, F. Perros, C. Guignabert, L. Tu, M. Humbert, I. Adcock, S. Wort (London, United Kingdom; Le Plessis-Robinson, France). Selective inhibition of BET bromodomain and their effect on nuclear factor-kappa B activation in pulmonary arterial hypertension. Eur Respir J 2013; 42: Suppl. 57, 1501

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014

The role of bromodomain-containing protein 4 in the constitutive activation of nuclear factor-kappa B in endothelial cells from patients with pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Year: 2012


Activation of AMPK inhibits pulmonary arterial remodeling
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015

Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016

Inhibition of the miRNA familiy miR-130 restores the expression of CDKN1A (p21) and ameliorates hypoxia-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014


Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling?
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015

Right heart hypertrophy in mice deficient of the mitochondrial regulator protein p66shc is decreased after chronic hypoxic exposure by a cyclophilin D dependent mechanism
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014

RASSF1A regulates ROS-HIF axis in hypoxia driven pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: novel insights
Year: 2016

Functional upregulation of PRMT2 in chronic hypoxia-induced pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 721s
Year: 2004

A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006


Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013

Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018



Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014


Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

Pulmonary vascular dysfunction in end-stage cystic fibrosis: role of NF-kappa B and endothelin-1
Source: Eur Respir J 2009; 34: 1329-1337
Year: 2009



Role of endothelin B receptor in Th2-induced pulmonary vascular hyperresponsiveness
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013

NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016

Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016